Intercell and GSK form strategic alliance to develop and commercialize innovative needle-free patch-based vaccines

Intercell and GSK form strategic alliance to develop and commercialize innovative needle-free patch-based vaccines

Vienna (Austria) / London (UK), December 11, 2009 - Intercell and GlaxoSmithKline Biologicals SA (GSK) today announced an agreement to form a strategic alliance to accelerate the development and commercialization of needle-free, patch-based vaccines. The agreement will include Intercell's candidate vaccine for travelers' diarrhea (TD) and an investigational single application pandemic influenza vaccine, as well as the use of the patch technology for other vaccines in GSK's portfolio.

Under the terms of the agreement, GSK will make an up-front cash contribution of EUR 33.6 (USD 49.4) million, in addition to an equity investment of up to EUR 84 (USD 123.5) million through a staggered shareholding purchase option of up to 5 % in Intercell. Included in the agreement are Intercell's investigational TD vaccine, currently in Phase III, and an investigational single application pandemic influenza vaccine in Phase II, as well as other potential future patch vaccines.

"This new partnership is combining the forces of Intercell's innovative needle-free vaccination program and technologies with a vaccine leader's strength in development and commercialization. In addition, we can pursue our business strategy of creating significant shareholder value as an independent company whilst continuing to develop one of the most innovative product pipelines in the industry," says Gerd Zettlmeissl, Chief Executive Officer of Intercell.

"This novel technology has real potential to change the way vaccines are delivered in the future. GSK has an extensive portfolio of vaccines and we believe needle-free vaccination could offer benefits such as simplified administration and increased compliance." said Jean Stephenne, President of GSK Biologicals. "This agreement demonstrates how, as an integral part of our R&D program, we not only look at new vaccines but also at alternative approaches to oral and intramuscular administration."

Each year, approximately 20 million international travelers develop TD while visiting endemic areas in Asia, Africa, and South America. Currently, there is no vaccine available to address this medical need. GSK and Intercell will collaborate on the TD Vaccine Patch, currently in phase III, to commercialize this vaccine once it has gained regulatory approval. The agreement will also include a collaboration between the two companies to further develop and co-market an innovative pandemic influenza vaccination approach. 

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.